Hospital Regional Universitario de Málaga

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC

  2026-526300-67-00· Phase 3· Summit Therapeutics Inc.· Source

• Not yet recruiting

  Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

  NCT07896265· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· K-Group Beta Inc.· Source

• Recruiting

  A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

  2026-525328-10-00· Phase 2· Medica Scientia Innovation Research S.L.· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial

  2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source

• Recruiting

  A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

  NCT07465757· Phase 2· Puma Biotechnology, Inc.· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Not yet recruiting

  Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

  NCT07684248· Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud· Source

• Not yet recruiting

  Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

  NCT07247786· Phase 2· Fundación GECP· Source

• Not yet recruiting

  A phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation

  2026-525964-17-00· Phase 2· Fundacion PETHEMA· Source

• Recruiting

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  UNLOAD-CHF Urea for Normalizing hyponatremia and reducing voLume Overload in Acute and Chronic Heart Failure

  2025-523981-26-03· Phase 3· Nutricion Medica S.L.· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  A study that compares Depigoid Olea (a medication to treat olive pollen allergies) and placebo in patients who have a runny nose and pink and itchy eyes due to olive pollen allergy.

  2026-525840-13-00· Phase 3· LETI Pharma S.L.U.· Source

• Recruiting

  Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

  2025-524793-42-00· Phase 2· Janssen Cilag International· Source

• Not yet recruiting

  Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.

  2025-524606-15-00· Phase 3· Tecnimede-Sociedade Tecnico-Medicinal S.A.· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Recruiting

  A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

  NCT07636811· Phase 2· Alnylam Pharmaceuticals· Source

• Recruiting

  Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

  NCT07864207· Phase 1/2· IDP Discovery Pharma S.L.· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.

  2025-522076-85-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

  NCT07673627· Phase 2· argenx· Source

• Recruiting

  Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)

  2025-521902-17-00· Phase 1/2· Idp Discovery Pharma S.L.· Source

• Recruiting

  Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib

  2025-521126-15-00· Phase 2· Grupo Espanol De Leucemia Mieloide Cronica (GELMC)· Source

• Recruiting

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

  NCT07478991· Phase 3· PETHEMA Foundation· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1)

  2025-524040-35-00· Phase 3· Generate Biomedicines Inc.· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Grass Immunotherapy for Rhinitis and Asthma (GIRA)

  2025-521736-10-00· Phase 3· LETI Pharma S.L.U.· Source

• Recruiting

  Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)

  2025-521709-42-00· Phase 3· LETI Pharma S.L.U.· Source

• Recruiting

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· Phase 2/3· Eikon Therapeutics· Source

• Recruiting

  Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  NCT07504458· Phase 3· Quetzal Therapeutics· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Recruiting

  An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

  NCT07620392· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Bayer· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

  NCT07242547· Phase 2· Fundación GECP· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

  NCT07416526· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

  NCT07264075· Phase 3· Groupe Oncologie Radiotherapie Tete et Cou· Source

• Recruiting

  A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy

  2025-522979-29-00· Phase 3· Fundacion PETHEMA· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 385.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer61 recruiting
• Colorectal cancer16 recruiting
• Childhood cancers14 recruiting
• Acute myeloid leukaemia9 recruiting
• Asthma8 recruiting
• Melanoma8 recruiting
• Gastric and oesophageal cancer7 recruiting
• Haemophilia6 recruiting
• Multiple myeloma6 recruiting
• Prostate cancer6 recruiting
• Metastatic breast cancer5 recruiting
• Multiple sclerosis5 recruiting
• Rheumatoid arthritis5 recruiting
• Coronary artery disease4 recruiting
• Head and neck cancer4 recruiting
• Liver and biliary tract cancer4 recruiting
• Lupus (SLE)4 recruiting
• Myasthenia gravis4 recruiting
• Pancreatic cancer4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Epilepsy3 recruiting
• Heart failure3 recruiting
• Parkinson disease3 recruiting
• Sarcoma3 recruiting
• Stroke3 recruiting
• Type 2 diabetes3 recruiting
• ALS (motor neurone disease)2 recruiting
• Alzheimer disease2 recruiting
• Bladder cancer2 recruiting
• Brain metastases2 recruiting
• Chronic myeloid leukaemia2 recruiting
• COPD2 recruiting
• Deep vein thrombosis and pulmonary embolism2 recruiting
• Endometrial cancer2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Neuroendocrine tumours2 recruiting
• Obesity2 recruiting
• Psoriasis2 recruiting
• Psoriatic arthritis2 recruiting
• Triple-negative breast cancer2 recruiting
• ANCA-associated vasculitis1 recruiting
• Atrial fibrillation1 recruiting
• Bipolar disorder1 recruiting
• Brain aneurysm1 recruiting
• Bronchiectasis1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Coeliac disease1 recruiting
• Crohn's disease1 recruiting
• Cytomegalovirus infection1 recruiting
• Depression1 recruiting
• Dilated cardiomyopathy1 recruiting
• Down syndrome1 recruiting
• Gaucher disease1 recruiting
• HIV1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Irritable bowel syndrome1 recruiting
• Kidney cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Spinal muscular atrophy1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Turner syndrome1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

  2025-524038-24-00· Phase 3· Praxis Precision Medicines Inc.· Source

• Completed

  Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP

  2024-515386-34-00· Phase 2· Nuvig Therapeutics Inc.· Source

• Active, not recruiting

  Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

  NCT06931405· Phase 2· Blueprint Medicines Corporation· Source

• Completed

  Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

  NCT06851962· Phase 4· Fundación para la Investigación del Hospital Clínico de Valencia· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  Dose-ranging study evaluating the efficacy and safety of EVO756 in adults with Chronic Spontaneous Urticaria.

  2024-518786-10-01· Phase 2· Evommune Inc.· Source

• Completed

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· Phase 3· H e x a l AG· Source

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Immutep S.A.S.· Source

• Recruiting

  Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures

  2024-514499-42-00· Phase 3· Neuraxpharm Pharmaceuticals S.L.· Source

• Completed

  An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures

  2024-517061-16-01· Phase 2· Praxis Precision Medicines Inc.· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

  NCT06754462· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

  NCT06613009· Phase 1· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Completed

  A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)

  2024-514559-13-00· Phase 2/3· Praxis Precision Medicines Inc.· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease

  2024-512986-15-00· Phase 2· Kiniksa Pharmaceuticals GmbH· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

  NCT06624228· Phase 3· UCB Biopharma SRL· Source

• Completed

  Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer

  2024-512754-16-01· Phase 3· Curium US LLC· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· AbbVie· Source

• Completed

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment

  2023-506509-21-00· Phase 1· Verge Genomics· Source

• Completed

  Predictive Factors for Medullary Thyroid Cancer Aggressiveness

  NCT06292988· Aristotle University Of Thessaloniki· Source

• Completed

  A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC

  2022-503007-22-00· Phase 2· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)

  2023-507304-32-00· Phase 4· Fundacio Privada Mon Clinic Barcelona· Source

• Active, not recruiting

  Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

  NCT05853575· Phase 2· Mirati Therapeutics Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Terminated

  Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

  NCT06268574· Phase 2· Ryvu Therapeutics SA· Source

• Completed

  A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)

  2023-505910-10-00· Phase 2· Ryvu Therapeutics S.A.· Source

• Completed

  Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.

  2022-502413-29-00· Phase 2· Asociacion Grupo Tratamiento De Tumores Digestivos· Source

• Completed

  Oral Nutritional Supplement in Type 2 Diabetes Subjects With or at Risk of Malnutrition

  NCT05913193· Abbott Nutrition· Source

• Completed

  Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

  NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Terminated

  IMM60 and Pembrolizumab in Melanoma and NSCLC

  NCT05709821· Phase 1/2· iOx Therapeutics· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

• Completed

  A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)

  2022-502880-39-00· Phase 2· Apcintex Limited· Source

• Completed

  A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

  NCT06073093· Phase 2· Sanofi· Source

• Completed

  A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

  2022-503108-26-00· Phase 1/2· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

  NCT06047444· Phase 3· Ipsen· Source

• Completed

  A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)

  NCT05604170· Phase 3· Marinus Pharmaceuticals Inc.· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours

  2023-504376-21-00· Phase 1· Peptomyc S.L.· Source

• Completed

  EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06390059· Phase 2· NovoCure Ltd.· Source

• Completed

  TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

  NCT03529448· Phase 1/2· Grupo Español de Investigación en Neurooncología· Source

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

  NCT05798520· Phase 2· Biogen· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

  NCT05929079· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

  NCT05856448· Phase 2· Lakefront Biotherapeutics NV· Source

Showing 50 of 161.